Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Agita Jukna

Squamous Cell Carcinoma “Transformation” Concurrent With Secondary T790M Mutation in Resistant EGFR -Mutated Adenocarcinomas

Journal of Thoracic Oncology

English

Related publications

Osimertinib for Secondary T790m-Mutation–Positive Squamous Cell Carcinoma Transformation After Afatinib Failure

Journal of Thoracic Oncology

English

P3.01-06 Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC

Journal of Thoracic Oncology

English

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Journal of Thoracic Oncology

English

Squamous Cell Transformation and EGFR T790M Mutation as Acquired Resistance Mechanisms in a Patient With Lung Adenocarcinoma Treated With a Tyrosine Kinase Inhibitor: A Case Report

English

P2.09-12 EGFR Mutation Status in Squamous Cell Carcinoma or Non-Small Cell Carcinoma Favor Squamous Cell Carcinoma Diagnosed From Small Lung Biopsies

Journal of Thoracic Oncology

English

P3.17-14 a Case of a Patient Harboring an EGFR -T790m Mutation Positive in Squamous Cell Lung Cancer

Journal of Thoracic Oncology

English

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

EGFR Mutation in Patients With Lung Adenosquamous Cell Carcinoma

Annals of Surgical Oncology

Oncology

Surgery

2017

English

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Agita Jukna

Squamous Cell Carcinoma “Transformation” Concurrent With Secondary T790M Mutation in Resistant EGFR -Mutated Adenocarcinomas

Related publications

Osimertinib for Secondary T790m-Mutation–Positive Squamous Cell Carcinoma Transformation After Afatinib Failure

P3.01-06 Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Squamous Cell Transformation and EGFR T790M Mutation as Acquired Resistance Mechanisms in a Patient With Lung Adenocarcinoma Treated With a Tyrosine Kinase Inhibitor: A Case Report

P2.09-12 EGFR Mutation Status in Squamous Cell Carcinoma or Non-Small Cell Carcinoma Favor Squamous Cell Carcinoma Diagnosed From Small Lung Biopsies

P3.17-14 a Case of a Patient Harboring an EGFR -T790m Mutation Positive in Squamous Cell Lung Cancer

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

EGFR Mutation in Patients With Lung Adenosquamous Cell Carcinoma

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study